EUVIMEDEUVIMED entdecken
Open Access

Outcomes of SMARCB1 ‐deficient sinonasal carcinoma: Largest single‐center cross‐sectional study

Robbie Woods iD, Daniel Scholfield iD, Lucas Axiotakis, Conall Fitzgerald, Dauren Adilbay iD, Jennifer Cracchiolo iD, Snehal Patel, Jatin Shah iD, Lara Dunn iD, David Pfister, Nancy Lee, Snjezana Dogan und 2 weitere

Head & Neck · 2024

DOI: 10.1002/hed.27859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Robbie Woods und 13 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: SMARCB1 Protein, Paranasal Sinus Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluate outcomes of SMARCB1‐deficient sinonasal carcinomas in the largest single‐institution study.

Methods

Retrospective cross‐sectional study of patients with SMARCB1‐deficient sinonasal carcinoma between 1998 and 2024. Disease‐specific survival (DSS) and recurrence‐free probability (RFP) at 1 and 5 years were measured by Kaplan–Meier method.

Results

There were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate analysis, cranial nerve involvement ( p = 0.01 for DSS) remained significantly worse for DSS and overall survival.

Conclusions

SMARCB1‐deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SMARCB1 ProteinParanasal Sinus NeoplasmsHumansMiddle AgedFemaleMaleCross-Sectional StudiesRetrospective StudiesAdultAgedDisease-Free SurvivalKaplan-Meier EstimatePrognosisNeoadjuvant TherapyTreatment OutcomeCarcinoma

Stichwörter der Autor:innen

INI‐1SMARCB‐1induction chemotherapysinonasal carcinomaskull base

Substanzen

SMARCB1 ProteinSMARCB1 protein, human

Autor:innen und Institutionen

  • Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Robbie Woods, Daniel Scholfield, Dauren Adilbay, Jennifer Cracchiolo, Jatin Shah, Lara Dunn, Ian Ganly

Förderung

  • NCI NIH HHS

Zitieren

APA

Woods, R., Scholfield, D., Axiotakis, L., Fitzgerald, C., Adilbay, D., Cracchiolo, J., Patel, S., Shah, J., Dunn, L., Pfister, D., Lee, N., Dogan, S., Ganly, I., & Cohen, M. (2024). Outcomes of SMARCB1 ‐deficient sinonasal carcinoma: Largest single‐center cross‐sectional study. Head & Neck. https://doi.org/10.1002/hed.27859

Vancouver

Woods R, Scholfield D, Axiotakis L, Fitzgerald C, Adilbay D, Cracchiolo J, et al. Outcomes of SMARCB1 ‐deficient sinonasal carcinoma: Largest single‐center cross‐sectional study. Head & Neck. 2024. doi:10.1002/hed.27859

BibTeX
@article{Woods2024,
  author = {Woods, Robbie and Scholfield, Daniel and Axiotakis, Lucas and Fitzgerald, Conall and Adilbay, Dauren and Cracchiolo, Jennifer and Patel, Snehal and Shah, Jatin and Dunn, Lara and Pfister, David and Lee, Nancy and Dogan, Snjezana and Ganly, Ian and Cohen, Marc},
  title = {Outcomes of SMARCB1 ‐deficient sinonasal carcinoma: Largest single‐center cross‐sectional study},
  journal = {Head & Neck},
  year = {2024},
  doi = {10.1002/hed.27859}
}
Kostenlos starten →